Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, Okeley NM, Sanderson RJ, Stone IJ, Zeng W, Gregson SJ, Masterson L, Tiberghien AC, Howard PW, Thurston DE, Law CL, Senter PD.

Bioconjug Chem. 2013 Jul 17;24(7):1256-63. doi: 10.1021/bc400217g. Epub 2013 Jun 28.

PMID:
23808985
2.

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, Zeng W, Harrington KH, Klussman K, Westendorf L, Meyer D, Bernstein ID, Senter PD, Benjamin DR, Drachman JG, McEarchern JA.

Blood. 2013 Aug 22;122(8):1455-63. doi: 10.1182/blood-2013-03-491506. Epub 2013 Jun 14.

3.

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.

McDonagh CF, Kim KM, Turcott E, Brown LL, Westendorf L, Feist T, Sussman D, Stone I, Anderson M, Miyamoto J, Lyon R, Alley SC, Gerber HP, Carter PJ.

Mol Cancer Ther. 2008 Sep;7(9):2913-23. doi: 10.1158/1535-7163.MCT-08-0295.

4.

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.

Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP.

Clin Cancer Res. 2008 Oct 1;14(19):6171-80. doi: 10.1158/1078-0432.CCR-08-0916. Epub 2008 Sep 22.

5.

In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.

Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):843-52.

6.

Contribution of linker stability to the activities of anticancer immunoconjugates.

Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, Senter PD.

Bioconjug Chem. 2008 Mar;19(3):759-65. doi: 10.1021/bc7004329. Epub 2008 Mar 4.

PMID:
18314937
7.

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, Havenith CE, Levy JN, Tiberghien A, Masterson LA, Barry C, D'Hooge F, Marafioti T, Parren PW, Williams DG, Howard PW, van Berkel PH, Hartley JA.

Mol Cancer Ther. 2016 Nov;15(11):2709-2721. Epub 2016 Aug 17.

PMID:
27535974
8.

Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.

Burke PJ, Toki BE, Meyer DW, Miyamoto JB, Kissler KM, Anderson M, Senter PD, Jeffrey SC.

Bioorg Med Chem Lett. 2009 May 15;19(10):2650-3. doi: 10.1016/j.bmcl.2009.03.145. Epub 2009 Apr 5.

PMID:
19386499
9.

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.

Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF.

Cancer Res. 2006 Feb 15;66(4):2328-37.

10.

Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S, Wong T, Melnick J, Theunissen JW, Flory MR, Houser D, Venstrom K, Levashova Z, Sauer P, Migone TS, van der Horst EH, Halcomb RL, Jackson DY.

Mol Pharm. 2015 Nov 2;12(11):3986-98. doi: 10.1021/acs.molpharmaceut.5b00432. Epub 2015 Oct 2.

PMID:
26393951
11.

Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.

Burke PJ, Senter PD, Meyer DW, Miyamoto JB, Anderson M, Toki BE, Manikumar G, Wani MC, Kroll DJ, Jeffrey SC.

Bioconjug Chem. 2009 Jun;20(6):1242-50. doi: 10.1021/bc9001097.

PMID:
19469529
12.

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA.

Clin Cancer Res. 2004 Oct 15;10(20):7063-70.

13.

Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.

Safavy A, Georg GI, Vander Velde D, Raisch KP, Safavy K, Carpenter M, Wang W, Bonner JA, Khazaeli MB, Buchsbaum DJ.

Bioconjug Chem. 2004 Nov-Dec;15(6):1264-74.

PMID:
15546192
14.

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, Bannister D, Jovanovic J, Fleming R, D'Hooge F, Mao S, Marrero AM, Korade M 3rd, Strout P, Xu L, Chen C, Wetzel L, Breen S, van Vlerken-Ysla L, Jalla S, Rebelatto M, Zhong H, Hurt EM, Hinrichs MJ, Huang K, Howard PW, Tice DA, Hollingsworth RE, Herbst R, Kamal A.

Mol Cancer Ther. 2017 May 18. doi: 10.1158/1535-7163.MCT-16-0825. [Epub ahead of print]

PMID:
28522587
15.

Preclinical characterization of SGN-70, a humanized antibody directed against CD70.

McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, Grewal IS, Law CL.

Clin Cancer Res. 2008 Dec 1;14(23):7763-72. doi: 10.1158/1078-0432.CCR-08-0493.

16.

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.

McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL.

Blood. 2007 Feb 1;109(3):1185-92. Epub 2006 Oct 12.

17.

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.

Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, Alley SC, Okeley N, Hayes B, Hernandez-Ilizaliturri FJ, McDonagh CF, Carter PJ, Benjamin D, Grewal IS.

Blood. 2009 Apr 30;113(18):4352-61. doi: 10.1182/blood-2008-09-179143. Epub 2009 Jan 15.

18.

Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.

VanBrunt MP, Shanebeck K, Caldwell Z, Johnson J, Thompson P, Martin T, Dong H, Li G, Xu H, D'Hooge F, Masterson L, Bariola P, Tiberghien A, Ezeadi E, Williams DG, Hartley JA, Howard PW, Grabstein KH, Bowen MA, Marelli M.

Bioconjug Chem. 2015 Nov 18;26(11):2249-60. doi: 10.1021/acs.bioconjchem.5b00359. Epub 2015 Sep 11.

PMID:
26332743
19.

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.

Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, Kim KM, Nesterova A, Anderson M, McEarchern JA, Law CL, Smith LM.

Br J Cancer. 2010 Aug 24;103(5):676-84. doi: 10.1038/sj.bjc.6605816. Epub 2010 Jul 27.

20.

Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.

Drake PM, Albers AE, Baker J, Banas S, Barfield RM, Bhat AS, de Hart GW, Garofalo AW, Holder P, Jones LC, Kudirka R, McFarland J, Zmolek W, Rabuka D.

Bioconjug Chem. 2014 Jul 16;25(7):1331-41. doi: 10.1021/bc500189z. Epub 2014 Jun 23.

Supplemental Content

Support Center